NDA 213036 · Amivas
Artesunate
Artesunate · Intravenous
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Apr 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
May 26, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
245
71 Phase 3, 11 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 26, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
- ARTESUNATE · ARTESUNATE 110MG/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Artesunate" as an intervention, any sponsor and status, largest first.
Shin Poong Pharmaceutical Co. Ltd.Industry
NCT03201770 · 8,572 participants · Start Jun 22, 2017 · Primary completion Apr 10, 2019
Drug: pyronaridine artesunate · For: Malaria,Falciparum
Sites: Yaoundé, Cameroon; Bouaké, Côte d’Ivoire; Kinshasa, Democratic Republic of the Congo · 5 sites in all
- FocaL Mass Drug Administration for Vivax Malaria EliminationPivotal-lookingRecruiting
University of California, San FranciscoAcademic, hospital or other
NCT05690841 · 7,530 participants (planned) · Start Oct 14, 2024 · Primary completion May 1, 2027
Drug: Focal Mass Drug Administration (fMDA) · For: Plasmodium Vivax Malaria; Malaria
Sites: Iquitos, Peru
- Assessment of Use of Rapid Diagnostic Testing in the Context of Home Management With ACTsPivotal-lookingCompleted
Mbarara University of Science and TechnologyAcademic, hospital or other
NCT00720811 · 6,456 participants · Start Oct 2009 · Primary completion Jan 2012
Drug: Artemether-lumefantrine combination; amoxycillin and 2 more · For: Malaria; Pneumonia
Sites: Saponé, Burkina Faso; Kassane, Ghana; Iganga, Uganda · 4 sites in all
- Mass-Drug Administration to Reduce Malaria TransmissionPivotal-lookingCompleted
Radboud University Medical CenterAcademic, hospital or other
NCT00509015 · 6,000 participants (planned) · Start Feb 2008 · Primary completion Aug 2008
Drug: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg); Artesunate (day 1,2,3: 4 mg/kg) and 2 more · For: Malaria, Falciparum
Sites: Moshi, Tanzania
- Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African ChildrenPivotal-lookingCompleted
Institute of Tropical Medicine, BelgiumAcademic, hospital or other
NCT00393679 · 4,112 participants · Start Jul 2007 · Primary completion Dec 2009
Drug: amodiaquine-artesunate (ASAQ); dihydroartemisinin-piperaquine (DHAPQ) and 2 more · For: Fever; Malaria
Sites: Bobo-Dioulasso, Burkina Faso; Lambaréné, Gabon; Manhiça, Mozambique · 8 sites in all
- Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With MalariaPivotal-lookingCompleted
Institute of Tropical Medicine, BelgiumAcademic, hospital or other
NCT00852423 · 3,428 participants · Start Jun 2010 · Primary completion Oct 2013
Drug: Dihydroartemisinin-piperaquine; Artesunate-mefloquine and 2 more · For: Malaria in Pregnancy
Sites: Nanoro, Burkina Faso; Nazoanga, Burkina Faso; Ejisu Sekyere East, Ghana · 7 sites in all
- Intermittent Preventive Treatment (IPTp) Versus Rapid Diagnostic Testing (RDT) and Treatment of Malaria in PregnancyPivotal-lookingCompleted
London School of Hygiene and Tropical MedicineAcademic, hospital or other
NCT00432367 · 3,333 participants · Start Feb 2007 · Primary completion Feb 2009
Drug: Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine · For: Malaria; Anaemia; Pregnancy
Sites: Juaben, Ghana
- Treatments for COVID-19: Canadian Arm of the SOLIDARITY TrialPivotal-lookingStatus unknown
Sunnybrook Health Sciences CentreAcademic, hospital or other
NCT04330690 · 2,900 participants (planned) · Start Mar 18, 2020 · Primary completion Mar 10, 2024
Drug: Artesunate; Imatinib and 3 more · For: COVID-19
Sites: Calgary, Canada; Edmonton, Canada; Kamloops, Canada · 53 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Artemether for severe malaria.
Esu EB, Effa EE, Opie ON, et al. · Cochrane Database Syst Rev 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Artemether for severe malaria.
Esu E, Effa EE, Opie ON, et al. · Cochrane Database Syst Rev 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Drugs for treating urinary schistosomiasis.
Danso-Appiah A, Utzinger J, Liu J, et al. · Cochrane Database Syst Rev 2008 · Meta-Analysis, Systematic Review
- Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria.
Pryce J, Hine P · Cochrane Database Syst Rev 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Pre-referral rectal artesunate for severe malaria.
Okebe J, Eisenhut M · Cochrane Database Syst Rev 2014 · Systematic Review
- Artesunate, imatinib, and infliximab in COVID-19: A rapid review and meta-analysis of current evidence.
Amani B, Zareei S, Amani B, et al. · Immun Inflamm Dis 2022 · Meta-Analysis, Review
Sponsor: Amivas
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.